Comparer des méthodes

	EORTC QLQ-C30	Questionnaire d'Impact de la Fibromyalgie
Domaine	Résultats de santé	Résultats de santé
Famille	Process / pipeline	Process / pipeline
Année d'origine	1993	1991
Auteur d'origine	Nico Aaronson et al.	Cynthia S. Burckhardt et al.
Type	Self-report quality of life questionnaire	Self-report symptom and functional impairment questionnaire
Source fondatrice	Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., ... & Takeda, F. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-376.	Burckhardt, C. S., Clark, S. R., & Bennett, R. M. (1991). The Fibromyalgia Impact Questionnaire: Development and validation. The Journal of Rheumatic Diseases, 18(5), 728-735.
Alias	QLQ-C30, EORTC QLQ-C30, Cancer Quality of Life Scale	FIQ, Fibromyalgia Impact, Fibromyalgia Questionnaire
Apparentées	5	4
Résumé	The EORTC QLQ-C30 is the most widely used international instrument for assessing quality of life in cancer patients. Developed by the European Organisation for Research and Treatment of Cancer in 1993, it measures physical, emotional, cognitive, and social functioning alongside cancer-specific symptoms and financial impact, making it the standard outcome measure in oncology clinical trials and patient care.	The FIQ is the most widely used patient-reported outcome measure for fibromyalgia disease burden. Developed by Cynthia Burckhardt and colleagues in 1991, this 10-item questionnaire quantifies how fibromyalgia affects physical function, work capacity, depression, anxiety, sleep, pain, and fatigue. The revised version (FIQR, 21 items) offers enhanced psychometric properties and is the current standard in fibromyalgia clinical trials and practice.